Pharma's Market
SPECIAL REPORT
MOST SHARED
- Marc Faber: 100% Chance of Global Recession
- Fresh Fears as EU Finalises Reform Plans
- What College Tuition Will Look Like in 18 Years
- Zero China Growth Is ‘Probable’: Gordon Chang
- Citigroup Lost $20 Million on Facebook IPO Trades
- 5 High-Yield Stocks Ready to Boost Dividends
- What Would Greek Exit Mean for the US Economy?
- GM Discloses $600,000 Contract With Ad Agency Tied to CFO's Wife
- A New Look at the ‘New Poor’
- Six Pack: Beer Buzz of the Week
- Greek Exit Could Trigger 50% Fall in Euro Stocks: Analyst
- Under Pressure, FHA Skews to Wealthier Home Buyers
- Big Stock Upside for Hudson City Deal: Analyst
- 5 High-Yield Stocks Ready to Boost Dividends
- Yoshikami: Four Things You Need to Know About Gold Now
- Steinbock: The Euro Zone Endgame Begins
- Option Bulls Take Another Shot on Idenix
- Citigroup Lost $20 Million on Facebook IPO Trades
- JPMorgan to Shake Up Risk Team After Big Loss: Report
- EU Finalizes Bank Reforms; Shifts Burden to Bondholders
- Spain's Bankia Eyes Stake Sales After Record Bailout
- EU Set to Launch Action Against China Over Telecom Aid
- JPMorgan to Shake Up Risk Team After Big Loss: Report
- Marc Faber: Chance of Global Recession Is Now 100%
- Cool Jobs: From Gold Stacker to Bed Tester
- 'Flash Sale' Sites: Gimmick, or Online Shopping Future?
RSS FEED
Pfizer Gives Avant A "Bases Loaded" Deal For Cancer Treatment
Text Size 
Reporter
 |
AP Bobby Murcer as New York Yankees broadcaster |
] announced it's doing a deal worth up to $440 million over time with a baby biotech called Avant Immunotherapeutics [AVAN
Loading...
()
] .It's a partnership on an experimental brain cancer treatment that Yankee center fielder and announcer Bobby Murcer tried in one of the clinical trials.
He's still recovering from the recent discovery of scar tissue--reportedly not a cancer recurrence--that required a biopsy and follow-up treatment that zapped his energy. So much so, that he hasn't been able to work in the broadcast booth this season.
The drug is another one of those therapeutic cancer vaccines that I've blogged about a lot in relation to Dendreon [DNDN
Loading...
()
]. But the Avant drug, which it got in a recent deal with the privately held Celldex Therapeutics, is for the most common and aggressive form of brain cancer.
Sadly, there really haven't been any medical breakthroughs for it in the past few decades and the prognosis is never very good.
Many biotech and drug companies are working on treatments. For example, Genentech [DNA
Loading...
()
] just announced it plans to file by the end of this year for Food and Drug Administration approval of its cancer drug Avastin for use on brain tumors.
This latest PFE deal is chump change for the company which is absolutely loaded with cash. But it's a potential game-changer for a tiny biotech like Avant. Pfizer's giving AVAN $40 million cash money up front, buying $10 million worth of stock, is on the hook for milestone payments over time of more than $390 million and double-digit royalties on sales if this drug or similar ones from Avant ever gets to market--whether for brain tumors or possibly other tumor types.
So, it's a huge deal for Avant, but a relatively cheap bet for Pfizer which needs to swing at nearly every pitch. Investors are waiting for Pfizer to hit one out of the park.
Questions? Comments?
Data is a real-time snapshot *Data is delayed at least 15 minutes
